Safety Study of FP-1039 To Treat Cancer

Five Prime Therapeutics

Status and phase: Completed; Phase 1

Conditions: Advanced Cancer

Treatments: Drug: FP-1039

Study type: Interventional

Funder types: Industry

Identifiers

NCT00687505

FP1039-001

Details and patient eligibility

About

The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.

Enrollment: 39 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with metastatic or locally advanced unresectable solid tumors for which standard curative or supportive measures do not exist or are no longer effective
• Male or female 18 years of age or older

Exclusion criteria

• Presence or history of melanoma
• Primary brain tumor
• Presence or history of glaucoma

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

39 participants in 1 patient group

1

Experimental group

Description:

Single ascending doses

Treatment:

Drug: FP-1039